{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:37:13Z","timestamp":1761917833710,"version":"build-2065373602"},"reference-count":79,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.soc.2016.07.008","type":"journal-article","created":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T08:01:26Z","timestamp":1479974486000},"page":"133-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Metastatic Anal Cancer and Novel Agents"],"prefix":"10.1016","volume":"26","author":[{"given":"Van","family":"Morris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"Eng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.soc.2016.07.008_bib1","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.soc.2016.07.008_bib2","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1245\/s10434-007-9491-8","article-title":"Outcomes of salvage surgery for squamous cell carcinoma of the anal canal","volume":"14","author":"Schiller","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.soc.2016.07.008_bib3","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijrobp.2006.12.052","article-title":"Predictors and patterns of recurrence after definitive chemoradiation for anal cancer","volume":"68","author":"Das","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1\u20132","key":"10.1016\/j.soc.2016.07.008_bib4","first-page":"5","article-title":"Metastatic anal cancer: the search for cure","volume":"29","author":"Cummings","year":"2006","journal-title":"Onkologie"},{"issue":"2","key":"10.1016\/j.soc.2016.07.008_bib5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cncr.20364","article-title":"Anal cancer incidence and\u00a0survival: the surveillance, epidemiology, and end results experience, 1973\u20132000","volume":"101","author":"Johnson","year":"2004","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.soc.2016.07.008_bib6","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM199711063371904","article-title":"Sexually transmitted infection as a cause of anal cancer","volume":"337","author":"Frisch","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.soc.2016.07.008_bib7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cncr.20365","article-title":"Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer","volume":"101","author":"Daling","year":"2004","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.soc.2016.07.008_bib8","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/jnci\/92.18.1500","article-title":"Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome","volume":"92","author":"Frisch","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.soc.2016.07.008_bib9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/ijc.25080","article-title":"Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005","volume":"127","author":"Sunesen","year":"2010","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.soc.2016.07.008_bib10","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1056\/NEJM200003163421107","article-title":"Carcinoma of the anal canal","volume":"342","author":"Ryan","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.soc.2016.07.008_bib11","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/ijc.24116","article-title":"Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis","volume":"124","author":"De Vuyst","year":"2009","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.soc.2016.07.008_bib12","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/ijc.24215","article-title":"Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions","volume":"124","author":"Hoots","year":"2009","journal-title":"Int J Cancer"},{"issue":"19","key":"10.1016\/j.soc.2016.07.008_bib13","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/jnci\/djq356","article-title":"Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence","volume":"102","author":"Kjaer","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.soc.2016.07.008_bib14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/jnci\/djq001","article-title":"Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2\/3: critical role of duration of infection","volume":"102","author":"Rodriguez","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.soc.2016.07.008_bib15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jnci\/92.9.709","article-title":"Evidence for a causal association between human papillomavirus and a subset of head and neck cancers","volume":"92","author":"Gillison","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"19","key":"10.1016\/j.soc.2016.07.008_bib16","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1056\/NEJMoa065497","article-title":"Case\u2013control study of human papillomavirus and oropharyngeal cancer","volume":"356","author":"D'Souza","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.soc.2016.07.008_bib17","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/cncr.22963","article-title":"Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers?","volume":"110","author":"Sturgis","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.soc.2016.07.008_bib18","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ijc.21009","article-title":"Penile cancer: importance of circumcision, human papillomavirus and smoking in in\u00a0situ and invasive disease","volume":"116","author":"Daling","year":"2005","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.soc.2016.07.008_bib19","first-page":"389","article-title":"Detection of human papillomavirus in squamous neoplasm of the penis","volume":"147","author":"Sarkar","year":"1992","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.soc.2016.07.008_bib20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/LGT.0b013e3182472947","article-title":"Prevalence of human papillomavirus types in invasive vulvar cancers and vulvar intraepithelial neoplasia 3 in the United States before vaccine introduction","volume":"16","author":"Gargano","year":"2012","journal-title":"J\u00a0Low Genit Tract Dis"},{"issue":"4951","key":"10.1016\/j.soc.2016.07.008_bib21","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1126\/science.2157286","article-title":"Association of human papillomavirus types 16 and 18 E6 proteins with p53","volume":"248","author":"Werness","year":"1990","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.soc.2016.07.008_bib22","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1128\/jvi.70.7.4509-4516.1996","article-title":"High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation","volume":"70","author":"Li","year":"1996","journal-title":"J\u00a0Virol"},{"issue":"24","key":"10.1016\/j.soc.2016.07.008_bib23","doi-asserted-by":"crossref","first-page":"9094","DOI":"10.1128\/MCB.23.24.9094-9103.2003","article-title":"Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in\u00a0vivo","volume":"23","author":"Balsitis","year":"2003","journal-title":"Mol Cell Biol"},{"issue":"11","key":"10.1016\/j.soc.2016.07.008_bib24","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.2015-0091","article-title":"Clinicopathologic features associated with human papillomavirus\/p16 in patients with metastatic squamous cell carcinoma of the anal canal","volume":"20","author":"Morris","year":"2015","journal-title":"Oncologist"},{"issue":"17","key":"10.1016\/j.soc.2016.07.008_bib25","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2013.52.3464","article-title":"Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal","volume":"32","author":"Serup-Hansen","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.soc.2016.07.008_bib26","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.ijrobp.2015.08.004","article-title":"Prognostic Relevance of HPV Infection and p16 overexpression in squamous cell anal cancer","volume":"93","author":"Mai","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.soc.2016.07.008_bib27","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.ejca.2015.01.058","article-title":"High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: different implications for vaccine prevention and prognosis","volume":"51","author":"Baricevic","year":"2015","journal-title":"Eur J Cancer"},{"issue":"19","key":"10.1016\/j.soc.2016.07.008_bib28","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"FUTURE II Study Group","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.soc.2016.07.008_bib29","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A\u00a09-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.soc.2016.07.008_bib30","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.soc.2016.07.008_bib31","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF02586980","article-title":"Combined therapy for cancer of the anal canal: a preliminary report","volume":"17","author":"Nigro","year":"1974","journal-title":"Dis Colon Rectum"},{"issue":"5","key":"10.1016\/j.soc.2016.07.008_bib32","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/0360-3016(91)90265-6","article-title":"Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C","volume":"21","author":"Cummings","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"10.1016\/j.soc.2016.07.008_bib33","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.soc.2016.07.008_bib34","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"issue":"35","key":"10.1016\/j.soc.2016.07.008_bib35","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.soc.2016.07.008_bib36","first-page":"478","article-title":"Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal","volume":"14","author":"Mullen","year":"2007","journal-title":"Ann\u00a0Surg Oncol"},{"issue":"3","key":"10.1016\/j.soc.2016.07.008_bib37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/(SICI)1097-0142(19990801)86:3<405::AID-CNCR7>3.0.CO;2-Q","article-title":"Effectiveness of surgical salvage therapy for patients with locally uncontrolled anal carcinoma after sphincter-conserving treatment","volume":"86","author":"Allal","year":"1999","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.soc.2016.07.008_bib38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF02303552","article-title":"Salvage abdominoperineal resection following combined chemotherapy and radiotherapy for epidermoid carcinoma of the anus","volume":"1","author":"Ellenhorn","year":"1994","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.soc.2016.07.008_bib39","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1046\/j.1365-2168.2002.02231.x","article-title":"Salvage abdominoperineal resection in anal epidermoid cancer","volume":"89","author":"Nilsson","year":"2002","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.soc.2016.07.008_bib40","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0002-9343(89)80702-8","article-title":"Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal","volume":"87","author":"Ajani","year":"1989","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.soc.2016.07.008_bib41","first-page":"861","article-title":"5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer","volume":"86","author":"Faivre","year":"1999","journal-title":"Bull Cancer"},{"issue":"2","key":"10.1016\/j.soc.2016.07.008_bib42","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000361051","article-title":"Carboplatin and paclitaxel treatment is effective in advanced anal cancer","volume":"87","author":"Kim","year":"2014","journal-title":"Oncology"},{"issue":"7","key":"10.1016\/j.soc.2016.07.008_bib43","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00384-008-0467-3","article-title":"Activity of paclitaxel in metastatic squamous anal carcinoma","volume":"23","author":"Alcindor","year":"2008","journal-title":"Int J Colorectal Dis"},{"issue":"12","key":"10.1016\/j.soc.2016.07.008_bib44","first-page":"4637","article-title":"Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy","volume":"31","author":"Abbas","year":"2011","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.soc.2016.07.008_bib45","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/1097-0142(20010801)92:3<642::AID-CNCR1365>3.0.CO;2-Z","article-title":"Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a phase II trial","volume":"92","author":"Hainsworth","year":"2001","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.soc.2016.07.008_bib46","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1093\/annonc\/mdt396","article-title":"DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma","volume":"24","author":"Kim","year":"2013","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.soc.2016.07.008_bib47","doi-asserted-by":"crossref","first-page":"11133","DOI":"10.18632\/oncotarget.2563","article-title":"The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal","volume":"5","author":"Eng","year":"2014","journal-title":"Oncotarget"},{"issue":"7407","key":"10.1016\/j.soc.2016.07.008_bib48","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.soc.2016.07.008_bib49","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/bjc.2015.37","article-title":"Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX study involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer","volume":"112","author":"Price","year":"2015","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.soc.2016.07.008_bib50","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1200\/JCO.2009.23.3452","article-title":"Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial","volume":"28","author":"Roth","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.soc.2016.07.008_bib51","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2016.07.008_bib52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/apm.12306","article-title":"KRAS and BRAF mutations in anal carcinoma","volume":"123","author":"Serup-Hansen","year":"2015","journal-title":"APMIS"},{"issue":"7","key":"10.1016\/j.soc.2016.07.008_bib53","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/annonc\/mdw152","article-title":"Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes","volume":"27","author":"Chung","year":"2016","journal-title":"Ann Oncol"},{"issue":"41","key":"10.1016\/j.soc.2016.07.008_bib54","doi-asserted-by":"crossref","first-page":"43594","DOI":"10.18632\/oncotarget.6202","article-title":"Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas","volume":"6","author":"Smaglo","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.soc.2016.07.008_bib55","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1309\/X4UADHVN317V2XMW","article-title":"Epidermal growth factor receptor expression in anal canal carcinoma","volume":"124","author":"Le","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.soc.2016.07.008_bib56","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/CAD.0000000000000383","article-title":"Epidermal growth factor receptor inhibition in metastatic anal cancer","volume":"27","author":"Rogers","year":"2016","journal-title":"Anticancer Drugs"},{"issue":"5","key":"10.1016\/j.soc.2016.07.008_bib57","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000259615","article-title":"Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status","volume":"77","author":"Lukan","year":"2009","journal-title":"Oncology"},{"issue":"4935","key":"10.1016\/j.soc.2016.07.008_bib58","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.soc.2016.07.008_bib59","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.soc.2016.07.008_bib60","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.soc.2016.07.008_bib61","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1200\/JCO.2008.18.9043","article-title":"Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"27","author":"Monk","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.soc.2016.07.008_bib62","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.soc.2016.07.008_bib63","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.soc.2016.07.008_bib64","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.soc.2016.07.008_bib65","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.soc.2016.07.008_bib66","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.soc.2016.07.008_bib67","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.soc.2016.07.008_bib68","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.soc.2016.07.008_bib69","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"issue":"5795","key":"10.1016\/j.soc.2016.07.008_bib70","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1126\/science.1131078","article-title":"Reversal of the TCR stop signal by CTLA-4","volume":"313","author":"Schneider","year":"2006","journal-title":"Science"},{"issue":"6029","key":"10.1016\/j.soc.2016.07.008_bib71","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.soc.2016.07.008_bib72","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1084\/jem.183.6.2533","article-title":"CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T\u00a0cells","volume":"183","author":"Krummel","year":"1996","journal-title":"J\u00a0Exp Med"},{"issue":"7","key":"10.1016\/j.soc.2016.07.008_bib73","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"10.1016\/j.soc.2016.07.008_bib74","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T\u00a0cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"10.1016\/j.soc.2016.07.008_bib75","first-page":"472","article-title":"Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects","volume":"62","author":"de Jong","year":"2002","journal-title":"Cancer Res"},{"issue":"15","key":"10.1016\/j.soc.2016.07.008_bib76","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-04-0831","article-title":"Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6","volume":"64","author":"de Jong","year":"2004","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.soc.2016.07.008_bib77","first-page":"636","article-title":"Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter","volume":"63","author":"Welters","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.soc.2016.07.008_bib78","doi-asserted-by":"crossref","unstructured":"Ott PA, Piha-Paul SA, Munster P, et\u00a0al. Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: preliminary safety and efficacy results from KEYNOTE-028. Paper presented at: European Cancer Congress, Vienna, September 26, 2015.","DOI":"10.1016\/S0959-8049(15)30008-3"},{"key":"10.1016\/j.soc.2016.07.008_bib79","doi-asserted-by":"crossref","unstructured":"Morris VK II, Ciombor KK, Salem ME, et\u00a0al. NCI9673: a multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA). Presented at: American Society of Clinical Oncology. Chicago, June 5, 2016.","DOI":"10.1200\/JCO.2016.34.15_suppl.3503"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320716300412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320716300412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:00:02Z","timestamp":1760961602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320716300412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1055320716300412"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2016.07.008","relation":{},"ISSN":["1055-3207"],"issn-type":[{"type":"print","value":"1055-3207"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metastatic Anal Cancer and Novel Agents","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2016.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}